Einzeltreffer — DigiBib

Purpose: The aim of this study was to evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using (18)F-fluorodeoxyglucose with IV contrast for depiction of suspected recurrent ovarian cancer and to assess the impact of PET/contrast-enhanced CT findings on clinical management, compared with PET/non-contrast-enhanced CT and CT component.

Methods: One hundred thirty-two women previously treated for ovarian cancer underwent PET/CT consisting of non-enhanced and contrast-enhanced CT for suspected recurrence. PET/contrast enhanced CT, PET/non-contrast-enhanced CT, and enhanced CT were interpreted by two experienced radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging, and clinical follow-up for longer than 6 months.

Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 78.8% (52 of 66), 90.9% (60 of 66), and 84.8% (112 of 132), respectively, whereas those of PET/non-contrast-enhanced CT were 74.2% (49 of 66), 90.9% (60 of 66), and 82.6% (109 of 132), respectively, and those of enhanced CT were 60.6% (40 of 66), 84.8% (56 of 66), and 72.7% (96 of 132), respectively. Sensitivity, specificity, and accuracy differed significantly among the three modalities (Cochran Q test: p = 0.0001, p = 0.018, and p < 0.0001, respectively). The findings of PET/contrast-enhanced CT resulted in a change of management for 51 of the 132 patients (39%) and had an effect on patient management in 16 patients (12%) diagnosed by enhanced CT alone and three patients (2%) diagnosed by PET/non-contrast-enhanced CT.

Conclusion: Integrated PET/contrast-enhanced CT is an accurate modality for assessing ovarian cancer recurrence and led to changes in the subsequent appropriate therapy.

Titel:	Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Autor/in / Beteiligte Person:	Kitajima, K ; Murakami, K ; Yamasaki, E ; Domeki, Y ; Kaji, Y ; Fukasawa, I ; Inaba, N ; Suganuma, N ; Sugimura, K
Link:	Full Text Finder (Volltext)
Zeitschrift:	European journal of nuclear medicine and molecular imaging, Jg. 35 (2008-08-01), Heft 8, S. 1439-48
Veröffentlichung:	Berlin : Springer-Verlag Berlin, 2002-, 2008
Medientyp:	academicJournal
ISSN:	1619-7070 (print)
DOI:	10.1007/s00259-008-0776-3
Schlagwort:	Adult Aged Contrast Media Female Humans Male Middle Aged Radiopharmaceuticals Reproducibility of Results Sensitivity and Specificity Subtraction Technique Systems Integration Fluorodeoxyglucose F18 Iopamidol analogs & derivatives Neoplasm Recurrence, Local diagnosis Ovarian Neoplasms diagnosis Positron-Emission Tomography methods Tomography, X-Ray Computed methods
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Comparative Study; Evaluation Study; Journal Article Language: English [Eur J Nucl Med Mol Imaging] 2008 Aug; Vol. 35 (8), pp. 1439-48. <i>Date of Electronic Publication: </i>2008 Apr 17. MeSH Terms: Fluorodeoxyglucose F18* ; Iopamidol / analogs & derivatives ; Neoplasm Recurrence, Local / diagnosis ; Ovarian Neoplasms / diagnosis ; Positron-Emission Tomography / methods ; Tomography, X-Ray Computed / *methods ; Adult ; Aged ; Contrast Media ; Female ; Humans ; Male ; Middle Aged ; Radiopharmaceuticals ; Reproducibility of Results ; Sensitivity and Specificity ; Subtraction Technique ; Systems Integration References: Radiographics. 2003 Mar-Apr;23(2):315-40; quiz 533. (PMID: 12640150) ; CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36. (PMID: 11577478) ; AJR Am J Roentgenol. 2004 Feb;182(2):393-8. (PMID: 14736669) ; J Clin Oncol. 2004 Nov 1;22(21):4357-68. (PMID: 15514377) ; Abdom Imaging. 2008 Jan-Feb;33(1):112-8. (PMID: 17404789) ; Cancer. 2004 Feb 1;100(3):544-52. (PMID: 14745871) ; Gynecol Oncol. 2007 Apr;105(1):17-22. (PMID: 17208284) ; N Engl J Med. 2004 Dec 9;351(24):2519-29. (PMID: 15590954) ; AJR Am J Roentgenol. 2006 Feb;186(2):308-19. (PMID: 16423932) ; N Engl J Med. 1996 Jan 4;334(1):1-6. (PMID: 7494563) ; J Clin Oncol. 2001 Oct 15;19(20):4054-7. (PMID: 11600607) ; J Nucl Med. 2006 Oct;47(10):1643-8. (PMID: 17015900) ; Gynecol Oncol. 2001 Jul;82(1):17-21. (PMID: 11426956) ; Gynecol Oncol. 2005 Nov;99(2):294-300. (PMID: 16051330) ; Semin Nucl Med. 2003 Jul;33(3):228-37. (PMID: 12931324) ; Gynecol Oncol. 2001 Nov;83(2):310-5. (PMID: 11606090) ; Radiology. 2003 Nov;229(2):526-33. (PMID: 14512512) ; Radiology. 2004 Nov;233(2):433-40. (PMID: 15516617) ; Radiographics. 2003 May-Jun;23(3):687-701. (PMID: 12740470) ; Cancer. 2000 Oct 1;89(7):1532-40. (PMID: 11013368) ; Eur Radiol. 2003 May;13(5):943-9. (PMID: 12695813) ; Eur J Gynaecol Oncol. 2000;21(6):599-602. (PMID: 11214619) ; J Nucl Med. 2000 Aug;41(8):1369-79. (PMID: 10945530) ; Br J Radiol. 2007 Jun;80(954):437-45. (PMID: 17329683) ; Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):480-6. (PMID: 17089122) ; J Nucl Med. 2005 Jul;46(7):1225-39. (PMID: 16000293) ; J Nucl Med. 2004 Jan;45 Suppl 1:56S-65S. (PMID: 14736836) ; Eur J Nucl Med. 1999 Oct;26(10):1363-78. (PMID: 10541839) ; Eur J Gynaecol Oncol. 1995;16(2):123-9. (PMID: 7641739) ; Radiology. 1995 Dec;197(3):619-26. (PMID: 7480729) ; Clin Imaging. 1998 Sep-Oct;22(5):364-70. (PMID: 9755401) ; Abdom Imaging. 2004 May-Jun;29(3):398-403. (PMID: 15354347) ; Radiology. 2000 Jun;215(3):761-7. (PMID: 10831697) ; Semin Surg Oncol. 2000 Jul-Aug;19(1):42-8. (PMID: 10883023) ; Eur J Nucl Med Mol Imaging. 2007 May;34(5):658-666. (PMID: 17180659) ; Am J Obstet Gynecol. 1985 Apr 1;151(7):981-6. (PMID: 3157319) ; Radiology. 2004 Sep;232(3):823-9. (PMID: 15273335) ; J Nucl Med. 2003 Aug;44(8):1200-9. (PMID: 12902408) ; Eur J Radiol. 2005 Nov;56(2):263-8. (PMID: 16233894) ; Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):36-44. (PMID: 16896664) ; Neoplasma. 2002;49(5):329-33. (PMID: 12458332) ; Radiology. 2005 Jun;235(3):918-26. (PMID: 15914479) ; Lancet. 1996 Jul 20;348(9021):191-2. (PMID: 8684165) Substance Nomenclature: 0 (Contrast Media) ; 0 (Radiopharmaceuticals) ; 0Z5B2CJX4D (Fluorodeoxyglucose F18) ; 17E17JBP8L (iomeprol) ; JR13W81H44 (Iopamidol) Entry Date(s): Date Created: 20080418 Date Completed: 20081027 Latest Revision: 20211020 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.